Children with arthritis face elevated cancer risk

The FDA has approved lutetium Lu 177 dotatate for pediatric patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

SpringWorks Therapeutics has initiated a new drug application for mirdametinib in neurofibromatosis type 1-associated plexiform neurofibromas.

Each year in the United States, there are approximately 700 to 800 cases of NB, of which 90% are diagnosed before the age of 5 years. More than half of these cases are considered high-risk.

Patients aged 12 years and up with completely resected Stage IIB/C melanoma can now be treated (adjuvant) with FDA-approved nivolumab (Opdivo; Bristol Meyers Squibb Company).

An expert in pediatric hematology and oncology discusses the important role of a child’s medical home in diagnosing and treating these disorders.

Annual Walk & Roll For Wishes raises vital funds to restore hope when hope is needed most